Alnylam Pharmaceuticals, Inc. (ALNY)
USD 241.95
(-7.71%)
USD 241.95
(-7.71%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.82 Billion USD | 7.99% |
| 2022 | 3.54 Billion USD | -2.66% |
| 2021 | 3.64 Billion USD | 6.93% |
| 2020 | 3.4 Billion USD | 42.25% |
| 2019 | 2.39 Billion USD | 52.09% |
| 2018 | 1.57 Billion USD | -21.05% |
| 2017 | 1.99 Billion USD | 57.96% |
| 2016 | 1.26 Billion USD | -8.92% |
| 2015 | 1.38 Billion USD | 28.43% |
| 2014 | 1.07 Billion USD | 156.72% |
| 2013 | 420.53 Million USD | 46.26% |
| 2012 | 287.52 Million USD | 1.99% |
| 2011 | 281.91 Million USD | -28.31% |
| 2010 | 393.26 Million USD | -18.31% |
| 2009 | 481.38 Million USD | -13.21% |
| 2008 | 554.67 Million USD | 12.33% |
| 2007 | 493.79 Million USD | 105.74% |
| 2006 | 240 Million USD | 144.04% |
| 2005 | 98.34 Million USD | 48.77% |
| 2004 | 66.1 Million USD | 87.89% |
| 2003 | 35.18 Million USD | 118.38% |
| 2002 | 16.11 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.82 Billion USD | -0.14% |
| 2024 Q2 | 4 Billion USD | 4.84% |
| 2024 Q3 | 4.2 Billion USD | 4.87% |
| 2023 Q4 | 3.82 Billion USD | -0.24% |
| 2023 FY | 3.82 Billion USD | 7.99% |
| 2023 Q3 | 3.83 Billion USD | 12.83% |
| 2023 Q1 | 3.39 Billion USD | -4.35% |
| 2023 Q2 | 3.4 Billion USD | 0.31% |
| 2022 Q3 | 3.53 Billion USD | 6.15% |
| 2022 Q2 | 3.33 Billion USD | -3.0% |
| 2022 Q1 | 3.43 Billion USD | -5.76% |
| 2022 FY | 3.54 Billion USD | -2.66% |
| 2022 Q4 | 3.54 Billion USD | 0.31% |
| 2021 Q4 | 3.64 Billion USD | 4.92% |
| 2021 FY | 3.64 Billion USD | 6.93% |
| 2021 Q3 | 3.47 Billion USD | -1.06% |
| 2021 Q1 | 3.25 Billion USD | -4.46% |
| 2021 Q2 | 3.5 Billion USD | 7.81% |
| 2020 Q1 | 2.27 Billion USD | -4.82% |
| 2020 Q2 | 3.37 Billion USD | 48.02% |
| 2020 Q3 | 3.3 Billion USD | -1.99% |
| 2020 Q4 | 3.4 Billion USD | 3.02% |
| 2020 FY | 3.4 Billion USD | 42.25% |
| 2019 Q1 | 2.01 Billion USD | 27.89% |
| 2019 FY | 2.39 Billion USD | 52.09% |
| 2019 Q4 | 2.39 Billion USD | -5.76% |
| 2019 Q3 | 2.54 Billion USD | -6.43% |
| 2019 Q2 | 2.71 Billion USD | 34.88% |
| 2018 Q1 | 1.92 Billion USD | -3.59% |
| 2018 Q2 | 1.78 Billion USD | -6.95% |
| 2018 FY | 1.57 Billion USD | -21.05% |
| 2018 Q4 | 1.57 Billion USD | -6.02% |
| 2018 Q3 | 1.67 Billion USD | -6.36% |
| 2017 Q3 | 1.35 Billion USD | -5.3% |
| 2017 Q1 | 1.13 Billion USD | -10.21% |
| 2017 FY | 1.99 Billion USD | 57.96% |
| 2017 Q4 | 1.99 Billion USD | 46.86% |
| 2017 Q2 | 1.43 Billion USD | 26.49% |
| 2016 Q4 | 1.26 Billion USD | -3.82% |
| 2016 Q3 | 1.31 Billion USD | -5.01% |
| 2016 Q1 | 1.31 Billion USD | -5.02% |
| 2016 Q2 | 1.38 Billion USD | 4.95% |
| 2016 FY | 1.26 Billion USD | -8.92% |
| 2015 Q2 | 1.53 Billion USD | -6.02% |
| 2015 Q1 | 1.62 Billion USD | 50.87% |
| 2015 Q3 | 1.43 Billion USD | -6.18% |
| 2015 Q4 | 1.38 Billion USD | -3.46% |
| 2015 FY | 1.38 Billion USD | 28.43% |
| 2014 Q2 | 1.03 Billion USD | -4.41% |
| 2014 Q4 | 1.07 Billion USD | 9.45% |
| 2014 Q1 | 1.08 Billion USD | 156.89% |
| 2014 FY | 1.07 Billion USD | 156.72% |
| 2014 Q3 | 986.35 Million USD | -4.48% |
| 2013 Q3 | 447.5 Million USD | -3.25% |
| 2013 Q4 | 420.53 Million USD | -6.03% |
| 2013 FY | 420.53 Million USD | 46.26% |
| 2013 Q1 | 471.57 Million USD | 64.02% |
| 2013 Q2 | 462.55 Million USD | -1.91% |
| 2012 Q1 | 340.29 Million USD | 20.71% |
| 2012 FY | 287.52 Million USD | 1.99% |
| 2012 Q4 | 287.52 Million USD | -10.81% |
| 2012 Q3 | 322.35 Million USD | 1.22% |
| 2012 Q2 | 318.47 Million USD | -6.41% |
| 2011 Q4 | 281.91 Million USD | -9.12% |
| 2011 FY | 281.91 Million USD | -28.31% |
| 2011 Q3 | 310.22 Million USD | -8.98% |
| 2011 Q2 | 340.82 Million USD | -7.65% |
| 2011 Q1 | 369.05 Million USD | -6.16% |
| 2010 Q3 | 412.6 Million USD | -6.26% |
| 2010 Q1 | 463.4 Million USD | -3.73% |
| 2010 Q2 | 440.18 Million USD | -5.01% |
| 2010 FY | 393.26 Million USD | -18.31% |
| 2010 Q4 | 393.26 Million USD | -4.69% |
| 2009 Q1 | 554.52 Million USD | -0.03% |
| 2009 Q3 | 495.66 Million USD | -4.43% |
| 2009 Q4 | 481.38 Million USD | -2.88% |
| 2009 Q2 | 518.65 Million USD | -6.47% |
| 2009 FY | 481.38 Million USD | -13.21% |
| 2008 Q3 | 580.18 Million USD | 0.02% |
| 2008 Q4 | 554.67 Million USD | -4.4% |
| 2008 Q2 | 580.04 Million USD | 19.29% |
| 2008 Q1 | 486.25 Million USD | -1.53% |
| 2008 FY | 554.67 Million USD | 12.33% |
| 2007 FY | 493.79 Million USD | 105.74% |
| 2007 Q3 | 505.09 Million USD | 129.94% |
| 2007 Q2 | 219.65 Million USD | -3.38% |
| 2007 Q1 | 227.34 Million USD | -5.28% |
| 2007 Q4 | 493.79 Million USD | -2.24% |
| 2006 Q2 | 147.11 Million USD | -4.28% |
| 2006 Q3 | 144.52 Million USD | -1.76% |
| 2006 FY | 240 Million USD | 144.04% |
| 2006 Q1 | 153.68 Million USD | 56.27% |
| 2006 Q4 | 240 Million USD | 66.06% |
| 2005 Q4 | 98.34 Million USD | 127.4% |
| 2005 Q2 | 50.86 Million USD | -13.89% |
| 2005 Q1 | 59.06 Million USD | -10.65% |
| 2005 FY | 98.34 Million USD | 48.77% |
| 2005 Q3 | 43.24 Million USD | -14.97% |
| 2004 Q1 | 39.33 Million USD | 11.81% |
| 2004 FY | 66.1 Million USD | 87.89% |
| 2004 Q4 | 66.1 Million USD | 5.7% |
| 2004 Q3 | 62.54 Million USD | -8.66% |
| 2004 Q2 | 68.47 Million USD | 74.06% |
| 2003 Q4 | 35.18 Million USD | 0.0% |
| 2003 FY | 35.18 Million USD | 118.38% |
| 2002 FY | 16.11 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | -157.368% |
| Alkermes plc | 2.13 Billion USD | -79.283% |
| Agenus Inc. | 313.91 Million USD | -1120.045% |
| Aptorum Group Limited | 20.64 Million USD | -18455.538% |
| Ardelyx, Inc. | 297.57 Million USD | -1187.013% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -400.277% |
| Bicycle Therapeutics plc | 595.34 Million USD | -543.305% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -5096.44% |
| ChromaDex Corporation | 54.96 Million USD | -6867.979% |
| Chimerix, Inc. | 212.77 Million USD | -1699.976% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -13446.36% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -768.517% |
| CRISPR Therapeutics AG | 2.22 Billion USD | -71.777% |
| Precision BioSciences, Inc. | 159.78 Million USD | -2296.956% |
| Dyadic International, Inc. | 8.21 Million USD | -46496.545% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -11966.415% |
| Fortress Biotech, Inc. | 167.52 Million USD | -2186.141% |
| Lantern Pharma Inc. | 43.64 Million USD | -8674.546% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -2273.839% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -26300.863% |
| Incyte Corporation | 6.78 Billion USD | 43.53% |
| IO Biotech, Inc. | 150.71 Million USD | -2441.09% |
| Jaguar Health, Inc. | 50.76 Million USD | -7444.629% |
| Novavax, Inc. | 1.85 Billion USD | -106.424% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -906.785% |
| Opthea Limited | 188.79 Million USD | -1928.633% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -359.734% |
| ContextLogic Inc. | 423 Million USD | -805.409% |
| MiMedx Group, Inc. | 239.04 Million USD | -1502.145% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -2104.552% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -73983.201% |
| NextCure, Inc. | 129.41 Million USD | -2859.31% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -6999.207% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -10327.401% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -11756.847% |
| Vaxcyte, Inc. | 1.4 Billion USD | -172.025% |
| PDS Biotechnology Corporation | 59.39 Million USD | -6348.686% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -497.908% |
| Pharming Group N.V. | 462.85 Million USD | -727.449% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -9801.448% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -509.315% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -20138.564% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -20138.564% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -2216.647% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -8356.908% |
| Acelyrin, Inc. | 742.69 Million USD | -415.677% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -58047.22% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -59713.837% |
| Summit Therapeutics Inc. | 202.94 Million USD | -1787.114% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -5049.488% |
| Senti Biosciences, Inc. | 119.48 Million USD | -3105.35% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -1577.256% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -2177.332% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -46249.752% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -80127.611% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -716.271% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -2997.28% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -1292.942% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -709.974% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -37800.841% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -1685.442% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -338181.107% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -825.445% |
| Immix Biopharma, Inc. | 19.92 Million USD | -19121.326% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -935.033% |
| MEI Pharma, Inc. | 41.37 Million USD | -9156.508% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -11718.429% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -1023.798% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -3167.119% |
| Fortress Biotech, Inc. | 167.52 Million USD | -2186.141% |
| Precigen, Inc. | 151.04 Million USD | -2435.622% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -11158.393% |
| AlloVir, Inc. | 190.79 Million USD | -1907.317% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -917.365% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -656.569% |
| ImmuCell Corporation | 43.8 Million USD | -8642.401% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -489.833% |
| Onconetix, Inc. | 88.82 Million USD | -4211.886% |
| PureTech Health plc | 693.97 Million USD | -451.877% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -3820.643% |
| Elevation Oncology, Inc. | 89.09 Million USD | -4198.841% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -61652.338% |
| Seer, Inc. | 436.26 Million USD | -777.871% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -4593.653% |
| Innoviva, Inc. | 1.24 Billion USD | -207.99% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -2792.156% |
| ESSA Pharma Inc. | 149.12 Million USD | -2468.284% |
| GlycoMimetics, Inc. | 45.31 Million USD | -8351.408% |
| GT Biopharma, Inc. | 14.1 Million USD | -27044.943% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -1143.9% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -1484.54% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -711.575% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -7454.451% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -3922.476% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -606288.975% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -576.25% |
| Aptose Biosciences Inc. | 12.92 Million USD | -29537.198% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -17218.58% |
| Soligenix, Inc. | 9.79 Million USD | -38991.074% |
| Century Therapeutics, Inc. | 360.69 Million USD | -961.817% |
| Kura Oncology, Inc. | 448.93 Million USD | -753.103% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -1307.273% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -22044.435% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -3353.101% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -1766.859% |
| Autolus Therapeutics plc | 375.38 Million USD | -920.265% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -1421.992% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -978.281% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -7695.083% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -479.29% |
| GRI Bio, Inc. | 2.95 Million USD | -129462.923% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -36013.139% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -2146.066% |
| IGM Biosciences, Inc. | 423.41 Million USD | -804.53% |
| INmune Bio, Inc. | 57 Million USD | -6618.97% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -1621.248% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -4462.572% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -14564.398% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -55541.021% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -4991.165% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -2500.796% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -2214.071% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -508.3% |
| Verastem, Inc. | 149.71 Million USD | -2458.062% |
| Abeona Therapeutics Inc. | 64 Million USD | -5884.0% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -647.799% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -2379.577% |
| Histogen Inc. | 19.07 Million USD | -19980.113% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -16808.833% |
| Surrozen, Inc. | 46.08 Million USD | -8211.372% |
| Organovo Holdings, Inc. | 6.34 Million USD | -60222.57% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -88788.786% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -2559.144% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -32351.11% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -4988.324% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -44855.601% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -955.153% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -21066.11% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -791.91% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -30267.626% |
| Apollomics, Inc. | 55.38 Million USD | -6814.763% |
| Amarin Corporation plc | 831.68 Million USD | -360.497% |
| Mesoblast Limited | 669.15 Million USD | -472.347% |
| Turnstone Biologics Corp. | 112.81 Million USD | -3294.832% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -565.188% |
| Synaptogenix, Inc. | 31.11 Million USD | -12209.317% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -31333.684% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -598.804% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -65119.853% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -52041.553% |
| Exelixis, Inc. | 2.94 Billion USD | -30.164% |
| Better Therapeutics, Inc. | 22.94 Million USD | -16593.022% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -950.609% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -385.576% |
| NLS Pharmaceutics AG | 1.84 Million USD | -207297.106% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -47901.701% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -25962.47% |
| Gritstone bio, Inc. | 177.76 Million USD | -2054.414% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -3915.391% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -21341.172% |
| Avid Bioservices, Inc. | 336.55 Million USD | -1037.959% |
| Insmed Incorporated | 1.32 Billion USD | -187.996% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -39677.137% |
| MediWound Ltd. | 66.45 Million USD | -5662.771% |
| OmniAb, Inc. | 401.98 Million USD | -852.742% |
| Alector, Inc. | 621.82 Million USD | -515.908% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -968.009% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -71113.834% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -6655.592% |
| Zai Lab Limited | 1.03 Billion USD | -269.574% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -700.47% |
| Aura Biosciences, Inc. | 255.07 Million USD | -1401.472% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -410.631% |
| Immunic, Inc. | 54.29 Million USD | -6953.316% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -1338.593% |
| Veracyte, Inc. | 1.13 Billion USD | -236.598% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -32294.068% |
| FibroGen, Inc. | 423.52 Million USD | -804.278% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -108920.211% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -80757.07% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -70438.641% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 66.385% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -43396.65% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -640.139% |
| TG Therapeutics, Inc. | 329.58 Million USD | -1062.024% |
| Galecto, Inc. | 38.22 Million USD | -9918.783% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -13255.698% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 12.102% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -1526.939% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -15316.955% |
| XBiotech Inc. | 227.24 Million USD | -1585.368% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -3915.391% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -2585.75% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -1239.512% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -2895.159% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -902.589% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | -156.864% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -949.737% |
| Vaxxinity, Inc. | 44.35 Million USD | -8534.997% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -640.846% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -20480.428% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -1155.493% |
| NexImmune, Inc. | 8.59 Million USD | -44464.844% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -35642.53% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -22261.141% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 88.422% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -17189.772% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -976250.171% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -2109.601% |
| Ainos, Inc. | 31.84 Million USD | -11927.836% |
| Pluri Inc. | 39.52 Million USD | -9589.276% |
| Prothena Corporation plc | 696.38 Million USD | -449.968% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -1255.153% |
| Celularity Inc. | 143.88 Million USD | -2561.691% |
| Rallybio Corporation | 115.62 Million USD | -3212.472% |
| Cue Biopharma, Inc. | 61.53 Million USD | -6124.411% |
| MeiraGTx Holdings plc | 458.16 Million USD | -735.912% |
| Omeros Corporation | 378.26 Million USD | -912.475% |
| Humacyte, Inc. | 128.22 Million USD | -2886.89% |
| Immunocore Holdings plc | 597 Million USD | -541.52% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -12152.087% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -5488.618% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -265.011% |
| CalciMedica, Inc. | 12.18 Million USD | -31331.104% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -1409.907% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -2140.902% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -1131.334% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -577.496% |
| Pulmatrix, Inc. | 33.95 Million USD | -11178.285% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -14008.451% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -2618.965% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -194.385% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -2841.784% |
| Cytokinetics, Incorporated | 824.31 Million USD | -364.613% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -18031.326% |
| Nutriband Inc. | 7.51 Million USD | -50848.537% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -4750.774% |
| Vor Biopharma Inc. | 209.82 Million USD | -1725.247% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 46.973% |
| Evogene Ltd. | 51.1 Million USD | -7394.726% |
| ProKidney Corp. | 420.55 Million USD | -810.679% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -6884.626% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -40128.657% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -600.955% |
| CorMedix Inc. | 82.05 Million USD | -4567.173% |
| BioLineRx Ltd. | 63.92 Million USD | -5891.208% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -851.365% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -13481.135% |
| Atai Life Sciences N.V. | 293.47 Million USD | -1204.997% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -2247.755% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -2905.761% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -581.441% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -3859.801% |
| MediciNova, Inc. | 66.26 Million USD | -5679.208% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -4254.71% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -85726.238% |
| GeoVax Labs, Inc. | 9.28 Million USD | -41155.948% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -551.079% |
| Biomea Fusion, Inc. | 199.92 Million USD | -1815.639% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | -101.236% |
| Mereo BioPharma Group plc | 66.49 Million USD | -5659.305% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -689.51% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -524.899% |
| Absci Corporation | 234.48 Million USD | -1533.35% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -52256.528% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -1026.797% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -2219.986% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -627.669% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -1279.178% |
| Allakos Inc. | 243.61 Million USD | -1472.136% |
| Imunon, Inc. | 21.91 Million USD | -17373.62% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -1386.212% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -516.215% |
| BioAtla, Inc. | 119.65 Million USD | -3100.689% |
| NLS Pharmaceutics AG | 1.84 Million USD | -207297.106% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -118840.373% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -495.778% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -3892.161% |
| XOMA Corporation | 234.3 Million USD | -1534.598% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -1631.137% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -2943.355% |
| aTyr Pharma, Inc. | 122.06 Million USD | -3037.523% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -2388.502% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -560.016% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -680.932% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -3366.927% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -25167.129% |
| Akari Therapeutics, Plc | 4.35 Million USD | -87842.135% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -22379.34% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -120.963% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -124086.037% |
| UroGen Pharma Ltd. | 178.31 Million USD | -2047.865% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -713.594% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -689080.605% |
| Orgenesis Inc. | 14.55 Million USD | -26218.582% |
| Entera Bio Ltd. | 11.76 Million USD | -32453.166% |
| GH Research PLC | 226.3 Million USD | -1592.391% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -6902.377% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -3464.801% |
| Xencor, Inc. | 952.69 Million USD | -302.006% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -49103.4% |
| Replimune Group, Inc. | 487.72 Million USD | -685.259% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -47351.837% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -490.63% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -124086.037% |
| Portage Biotech Inc. | 7.77 Million USD | -49133.578% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -85726.238% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -1282.903% |
| OncoCyte Corporation | 74.89 Million USD | -5013.871% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -188262.659% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -66084.833% |
| Purple Biotech Ltd. | 44.3 Million USD | -8544.937% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -11122.763% |
| scPharmaceuticals Inc. | 94.47 Million USD | -3953.684% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -21124.1% |
| HilleVax, Inc. | 344.43 Million USD | -1011.934% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -120488.161% |
| Tharimmune, Inc. | 10.94 Million USD | -34887.598% |
| Genprex, Inc. | 10.67 Million USD | -35791.917% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -671.85% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -3879.013% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -157768.096% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -91844.166% |
| OKYO Pharma Limited | 1.54 Million USD | -248389.551% |
| Savara Inc. | 177.56 Million USD | -2056.901% |
| Curis, Inc. | 77.28 Million USD | -4855.721% |
| Daré Bioscience, Inc. | 21.28 Million USD | -17895.683% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -5888.978% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -47264.333% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -19671.204% |
| BeiGene, Ltd. | 5.8 Billion USD | 34.028% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -31372.43% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | -83.371% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -969.945% |
| Erasca, Inc. | 395.29 Million USD | -868.861% |
| bluebird bio, Inc. | 619.16 Million USD | -518.56% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -88485.545% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 44.021% |
| DBV Technologies S.A. | 182.98 Million USD | -1992.991% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -88485.545% |
| Moderna, Inc. | 18.42 Billion USD | 79.215% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -20923.659% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -32956.102% |
| Molecular Templates, Inc. | 35.38 Million USD | -10724.068% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -2669.956% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -385.463% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -1160.845% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -3584.49% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -722.521% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -1121.898% |
| MacroGenics, Inc. | 306.82 Million USD | -1148.25% |
| RenovoRx, Inc. | 1.46 Million USD | -261146.93% |
| Adicet Bio, Inc. | 207.29 Million USD | -1747.551% |
| Prime Medicine, Inc. | 193.85 Million USD | -1875.682% |
| Aditxt, Inc. | 44.57 Million USD | -8491.35% |
| Adagene Inc. | 115.72 Million USD | -3209.357% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -85883.778% |
| Quantum-Si incorporated | 298.25 Million USD | -1184.117% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | -157.48% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -49579.84% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -990.261% |
| SciSparc Ltd. | 11.18 Million USD | -34150.402% |
| Vericel Corporation | 353.65 Million USD | -982.936% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -31260.048% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -6630.824% |
| Generation Bio Co. | 374.75 Million USD | -921.961% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -1403.884% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -2315.307% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -1021.931% |
| Invivyd, Inc. | 229.18 Million USD | -1571.116% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -353.788% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -31371.651% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -1999.83% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -18651.861% |
| 2seventy bio, Inc. | 565.42 Million USD | -577.344% |
| ADMA Biologics, Inc. | 329.18 Million USD | -1063.454% |
| Clene Inc. | 52.34 Million USD | -7217.17% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -6420.684% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -2848.466% |
| GeoVax Labs, Inc. | 9.28 Million USD | -41155.948% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -485.878% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -3596.398% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -2837.34% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -3825.987% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -5294.425% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -1478.987% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | -95.393% |
| Evaxion Biotech A/S | 12.88 Million USD | -29615.208% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -1419.432% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -408.827% |
| Trevena, Inc. | 40.6 Million USD | -9332.04% |
| Surrozen, Inc. | 46.08 Million USD | -8211.372% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -1595.71% |
| Cingulate Inc. | 3.49 Million USD | -109593.547% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -22931.331% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -5730.233% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -32677.084% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -1326.308% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -411.362% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -2942.195% |
| Clearmind Medicine Inc. | 4.32 Million USD | -88464.65% |
| Kronos Bio, Inc. | 213.27 Million USD | -1695.714% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -2296.911% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -44638.401% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -939.344% |
| Statera Biopharma, Inc. | 21.16 Million USD | -17991.341% |
| ImmunityBio, Inc. | 504.45 Million USD | -659.216% |
| Korro Bio, Inc. | 221.66 Million USD | -1627.794% |
| Kineta, Inc. | 10.28 Million USD | -37152.018% |
| BioVie Inc. | 25.2 Million USD | -15092.905% |
| Codexis, Inc. | 136.56 Million USD | -2704.52% |
| Celularity Inc. | 143.88 Million USD | -2561.691% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -502.796% |
| Celcuity Inc. | 191.21 Million USD | -1902.872% |
| Virax Biolabs Group Limited | 5.48 Million USD | -69737.74% |
| Cibus, Inc. | 544.41 Million USD | -603.491% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -2942.147% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -18542.329% |
| IN8bio, Inc. | 33.7 Million USD | -11261.595% |
| Kodiak Sciences Inc. | 479.37 Million USD | -698.937% |
| Annexon, Inc. | 297.67 Million USD | -1186.602% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -2113.676% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -2685.995% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -18143.605% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -28.087% |
| Eyenovia, Inc. | 28.77 Million USD | -13207.725% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -1561.351% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -52916.058% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -6186.118% |
| Arcellx, Inc. | 825.13 Million USD | -364.154% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -4591.353% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -728.485% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -12354.894% |
| Moolec Science SA | 24.05 Million USD | -15823.804% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -1134.947% |
| Geron Corporation | 394.07 Million USD | -871.863% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -3665.49% |
| Royalty Pharma plc | 16.38 Billion USD | 76.621% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -543.712% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -54653.128% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -31743.181% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -1594.187% |
| Humacyte, Inc. | 128.22 Million USD | -2886.89% |
| Structure Therapeutics Inc. | 482.01 Million USD | -694.553% |
| 89bio, Inc. | 596.26 Million USD | -542.307% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -1418.878% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -206920.541% |
| Genelux Corporation | 27.89 Million USD | -13630.613% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -4183.838% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -1569.309% |
| Notable Labs, Ltd. | 19.54 Million USD | -19499.202% |
| Liquidia Corporation | 120.43 Million USD | -3080.145% |
| Mustang Bio, Inc. | 17.74 Million USD | -21486.518% |
| Immunovant, Inc. | 666.71 Million USD | -474.443% |
| Quantum-Si incorporated | 298.25 Million USD | -1184.117% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -2552.253% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -6971.418% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -2081.696% |
| Acasti Pharma Inc. | 73.3 Million USD | -5124.939% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -84031.01% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -14564.398% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | -296.962% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -73694.615% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -16711.729% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -7321.817% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -2019.574% |
| PepGen Inc. | 143.05 Million USD | -2577.264% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -9921.404% |
| United Therapeutics Corporation | 7.16 Billion USD | 46.562% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -19862.888% |
| Solid Biosciences Inc. | 164.93 Million USD | -2221.998% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -65119.853% |
| Immuneering Corporation | 102.58 Million USD | -3633.389% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -88788.786% |
| Silo Pharma, Inc. | 7.74 Million USD | -49342.426% |
| Belite Bio, Inc | 94.64 Million USD | -3946.702% |
| XOMA Corporation | 234.3 Million USD | -1534.598% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -1542.4% |
| Bionomics Limited | 27.64 Million USD | -13751.738% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -854.121% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -3466.395% |
| uniQure N.V. | 831.68 Million USD | -360.494% |
| Cassava Sciences, Inc. | 151.66 Million USD | -2425.257% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -85883.778% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -1298.353% |
| Forte Biosciences, Inc. | 38.98 Million USD | -9725.244% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -93928.304% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -10298.523% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -52916.058% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -108920.211% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -32298.951% |
| Altimmune, Inc. | 210.64 Million USD | -1718.211% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -392.348% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -3466.395% |
| Compugen Ltd. | 121.33 Million USD | -3056.477% |
| Peak Bio, Inc. | 2.59 Million USD | -147406.466% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -2122.449% |
| Benitec Biopharma Inc. | 52.21 Million USD | -7235.53% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -1020.31% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -10913.948% |
| Zura Bio Limited | 100.84 Million USD | -3697.864% |
| PolyPid Ltd. | 15.37 Million USD | -24814.65% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -3110.67% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -10913.948% |
| Instil Bio, Inc. | 325.63 Million USD | -1076.145% |
| argenx SE | 4.54 Billion USD | 15.687% |
| Immunome, Inc. | 148.54 Million USD | -2478.349% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -2341.358% |
| Verona Pharma plc | 308.12 Million USD | -1142.967% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -4304.236% |
| Shattuck Labs, Inc. | 159.56 Million USD | -2300.216% |
| CervoMed Inc. | 9.97 Million USD | -38304.331% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -1932.241% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -33530.839% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -2034.768% |
| Moolec Science SA | 24.05 Million USD | -15823.804% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -62505.517% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -2114.515% |
| AnaptysBio, Inc. | 452.38 Million USD | -746.59% |
| Design Therapeutics, Inc. | 289.64 Million USD | -1222.276% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -5159.018% |
| NeurAxis, Inc. | 509.49 Thousand USD | -751596.768% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -70588.077% |
| Lumos Pharma, Inc. | 40.63 Million USD | -9324.381% |
| Achilles Therapeutics plc | 161.45 Million USD | -2272.089% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -4304.236% |
| 180 Life Sciences Corp. | 5.25 Million USD | -72718.661% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -5338.023% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -44638.401% |
| Nutriband Inc. | 7.51 Million USD | -50848.537% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -1403.765% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -1821.656% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -4925.298% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -6512.819% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -627.367% |
| Palisade Bio, Inc. | 14.05 Million USD | -27155.053% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -1721.194% |
| Beam Therapeutics Inc. | 1.45 Billion USD | -162.372% |
| Neurogene Inc. | 222.57 Million USD | -1620.73% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -492.291% |
| AEON Biopharma, Inc. | 6.84 Million USD | -55851.497% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -745.381% |
| Sesen Bio, Inc. | 189.17 Million USD | -1924.528% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -1308.733% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -27831.128% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -390.789% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -1334.444% |
| Athira Pharma, Inc. | 160.24 Million USD | -2290.015% |
| Vaccinex, Inc. | 3.63 Million USD | -105377.279% |
| HCW Biologics Inc. | 28.51 Million USD | -13331.738% |
| XOMA Corporation | 234.3 Million USD | -1534.598% |
| Nektar Therapeutics | 398.03 Million USD | -862.202% |
| Arvinas, Inc. | 1.3 Billion USD | -193.567% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -22379.34% |
| Merus N.V. | 458.49 Million USD | -735.317% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -1774.03% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -2025.302% |
| Rezolute, Inc. | 132.73 Million USD | -2785.315% |
| Clene Inc. | 52.34 Million USD | -7217.17% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -25562.767% |
| BeyondSpring Inc. | 24.8 Million USD | -15338.084% |
| Synlogic, Inc. | 75.55 Million USD | -4969.332% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -32186.967% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -40800.043% |
| Peak Bio, Inc. | 2.59 Million USD | -147406.466% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -2090.593% |
| Krystal Biotech, Inc. | 818.35 Million USD | -367.997% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -1492.876% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -427.686% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -106964.403% |
| MannKind Corporation | 475.19 Million USD | -705.955% |
| Ikena Oncology, Inc. | 192.09 Million USD | -1893.774% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -28536.758% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -3186.35% |
| Gossamer Bio, Inc. | 311.91 Million USD | -1127.856% |
| CohBar, Inc. | 16.36 Million USD | -23301.918% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -10791.79% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -52256.528% |
| Legend Biotech Corporation | 1.84 Billion USD | -107.176% |
| Mural Oncology plc | 301.74 Million USD | -1169.244% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -12169.358% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -67322.657% |
| Disc Medicine, Inc. | 367.99 Million USD | -940.74% |
| Champions Oncology, Inc. | 26.13 Million USD | -14555.901% |
| REGENXBIO Inc. | 573.97 Million USD | -567.261% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -141323.921% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -2380.717% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -31615.909% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -1026.319% |
| Vaxart, Inc. | 91.83 Million USD | -4070.62% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -6293.375% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -2482.053% |
| Cellectis S.A. | 334.27 Million USD | -1045.744% |
| Longeveron Inc. | 12.17 Million USD | -31349.171% |
| Repare Therapeutics Inc. | 253.9 Million USD | -1408.415% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -17.316% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -1806.864% |
| Revolution Medicines, Inc. | 2.08 Billion USD | -83.371% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -235584.923% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -1279.088% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -2248.208% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -2660.393% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -14906.191% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 83.151% |
| Denali Therapeutics Inc. | 1.15 Billion USD | -231.903% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -31260.048% |
| Veru Inc. | 50.59 Million USD | -7469.542% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -8307.525% |
| Cingulate Inc. | 3.49 Million USD | -109593.547% |
| Passage Bio, Inc. | 150.54 Million USD | -2444.01% |
| Context Therapeutics Inc. | 16.06 Million USD | -23743.262% |
| Exicure, Inc. | 11.58 Million USD | -32973.23% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -918.455% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -2269.359% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -21820.101% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -1050.996% |
| Nuvalent, Inc. | 732.38 Million USD | -422.933% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -25528.077% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -4176.615% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -26888.091% |
| OmniAb, Inc. | 401.98 Million USD | -852.742% |
| Anew Medical, Inc. | 19.45 Million USD | -19584.875% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -14229.868% |
| Lipocine Inc. | 23 Million USD | -16550.876% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -2639.405% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -1153.377% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -4462.572% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -3051.127% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -48165.658% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -334.09% |
| Ocugen, Inc. | 64.54 Million USD | -5833.475% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -2975.196% |
| Q32 Bio Inc. | 306.11 Million USD | -1151.108% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -90914.259% |
| Alumis Inc. Common Stock | 89.61 Million USD | -4173.847% |
| Equillium, Inc. | 50.53 Million USD | -7479.418% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -4993.264% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -9179.266% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -225074.074% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -14550.855% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -5843.235% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -102657.282% |
| Dominari Holdings Inc. | 57.55 Million USD | -6553.949% |
| Edesa Biotech, Inc. | 8.89 Million USD | -42978.647% |
| vTv Therapeutics Inc. | 11.01 Million USD | -34660.211% |
| Bio-Techne Corporation | 2.81 Billion USD | -36.14% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -308.687% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -371.981% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -1279.317% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -9083.924% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -473.689% |
| Nkarta, Inc. | 378.88 Million USD | -910.829% |
| BioCardia, Inc. | 2.98 Million USD | -128118.279% |
| Iterum Therapeutics plc | 26.25 Million USD | -14485.018% |